Cargando…

Effectiveness of pyronaridine-artesunate against Plasmodium malariae, Plasmodium ovale spp, and mixed-Plasmodium infections: a post-hoc analysis of the CANTAM-Pyramax trial

BACKGROUND: High-quality evidence for the therapeutic efficacy and effectiveness of antimalarials for infections caused by Plasmodium malariae, Plasmodium ovale spp, and mixed-Plasmodium infections is scarce. In this study, we aimed to analyse the efficacy of pyronaridine–artesunate for the treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Groger, Mirjam, Tona Lutete, Gaston, Mombo-Ngoma, Ghyslain, Ntamabyaliro, Nsengi Y, Kahunu Mesia, Gauthier, Muena Mujobu, Trésor Bodjick, Dimessa Mbadinga, Lia Betty, Zoleko Manego, Rella, Egger-Adam, Diane, Borghini-Fuhrer, Isabelle, Shin, Jangsik, Miller, Robert, Arbe-Barnes, Sarah, Duparc, Stephan, Ramharter, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9329129/ https://www.ncbi.nlm.nih.gov/pubmed/35654079 http://dx.doi.org/10.1016/S2666-5247(22)00092-1

Ejemplares similares

Efficacy and safety of pyronaridine-artesunate (Pyramax(®)) for the treatment of uncomplicated Plasmodium vivax malaria in Northwest Ethiopia
por: Mohammed, Hussein, et al.
Publicado: (2022)

Description of Plasmodium falciparum infections in central Gabon demonstrating high parasite densities among symptomatic adolescents and adults
por: Zoleko Manego, Rella, et al.
Publicado: (2019)

Therapeutic efficacy of pyronaridine-artesunate (Pyramax(®)) against uncomplicated Plasmodium falciparum infection at Hamusit Health Centre, Northwest Ethiopia
por: Alebachew, Mihreteab, et al.
Publicado: (2023)

DNA recovery from archived RDTs for genetic characterization of Plasmodium falciparum in a routine setting in Lambaréné, Gabon
por: Nguyen, The Trong, et al.
Publicado: (2019)

Pyronaridine–artesunate real-world safety, tolerability, and effectiveness in malaria patients in 5 African countries: A single-arm, open-label, cohort event monitoring study
por: Tona Lutete, Gaston, et al.
Publicado: (2021)

Evidence for in vitro and in vivo activity of the antimalarial pyronaridine against Schistosoma
por: Koehne, Erik, et al.
Publicado: (2021)

Correction: Evidence for in vitro and in vivo activity of the antimalarial pyronaridine against Schistosoma
por: Koehne, Erik, et al.
Publicado: (2022)

Histone deacetylase inhibitors with high in vitro activities against Plasmodium falciparum isolates collected from Gabonese children and adults
por: Koehne, Erik, et al.
Publicado: (2019)

Pyronaridine‐artesunate for treating uncomplicated Plasmodium falciparum malaria
por: Pryce, Joseph, et al.
Publicado: (2019)

Pyronaridine‐artesunate for treating uncomplicated Plasmodium falciparum malaria
por: Pryce, Joseph, et al.
Publicado: (2022)

Community health workers in clinical research at the example of a phase IIIb/ IV antimalarial drug trial conducted in five African countries
por: Groger, Mirjam, et al.
Publicado: (2023)

Efficacy and Safety of Pyronaridine–Artesunate for the Treatment of Uncomplicated Plasmodium falciparum and Plasmodium vivax Malaria in Myanmar
por: Han, Kay Thwe, et al.
Publicado: (2020)

Artesunate plus pyronaridine for treating uncomplicated Plasmodium falciparum malaria
por: Bukirwa, Hasifa, et al.
Publicado: (2014)

Multinormal in vitro distribution of Plasmodium falciparum susceptibility to piperaquine and pyronaridine
por: Pascual, Aurélie, et al.
Publicado: (2015)

Efficacy and safety of ivermectin for the treatment of Plasmodium falciparum infections in asymptomatic male and female Gabonese adults – a pilot randomized, double-blind, placebo-controlled single-centre phase Ib/IIa clinical trial
por: Ekoka Mbassi, Dorothea, et al.
Publicado: (2023)

Safety and tolerability of artesunate-amodiaquine, artemether-lumefantrine and quinine plus clindamycin in the treatment of uncomplicated Plasmodium falciparum malaria in Kinshasa, the Democratic Republic of the Congo
por: Lula Ntamba, Yves, et al.
Publicado: (2019)

Plasmodium falciparum gametocyte dynamics after pyronaridine–artesunate or artemether–lumefantrine treatment
por: Roth, Johanna M., et al.
Publicado: (2018)

A randomized controlled trial comparing the effectiveness of individual versus household treatment for Scabies in Lambaréné, Gabon
por: Matthewman, Julian, et al.
Publicado: (2020)

Global gene expression profiling of Plasmodium falciparum in response to the anti-malarial drug pyronaridine
por: Kritsiriwuthinan, Kanyanan, et al.
Publicado: (2011)

Prospective Clinical and Molecular Evaluation of Potential Plasmodium ovale curtisi and wallikeri Relapses in a High-transmission Setting
por: Groger, Mirjam, et al.
Publicado: (2019)

Non-reassuring fetal status: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data
por: Gravett, Courtney, et al.
Publicado: (2016)

Detection of the Malaria causing Plasmodium Parasite in Saliva from Infected Patients using Topoisomerase I Activity as a Biomarker
por: Hede, Marianne Smedegaard, et al.
Publicado: (2018)

In vitro activity of pyronaridine against Plasmodium falciparum and comparative evaluation of anti-malarial drug susceptibility assays
por: Kurth, Florian, et al.
Publicado: (2009)

Absence of association between pyronaridine in vitro responses and polymorphisms in genes involved in quinoline resistance in Plasmodium falciparum
por: Pradines, Bruno, et al.
Publicado: (2010)

In vitro growth of Plasmodium falciparum in neonatal blood
por: Sauerzopf, Ulrich, et al.
Publicado: (2014)

The Plasmodium falciparum chloroquine resistance transporter is associated with the ex vivo P. falciparum African parasite response to pyronaridine
por: Madamet, Marylin, et al.
Publicado: (2016)

Plasmodium falciparum pfhrp2 and pfhrp3 gene deletions among patients in the DRC enrolled from 2017 to 2018
por: McCaffery, Jessica N., et al.
Publicado: (2021)

Effectiveness of antimalarial drug combinations in treating concomitant urogenital schistosomiasis in malaria patients in Lambaréné, Gabon: A non-randomised event-monitoring study
por: Zoleko-Manego, Rella, et al.
Publicado: (2022)

Pyronaridine-Artesunate versus Chloroquine in Patients with Acute Plasmodium vivax Malaria: A Randomized, Double-Blind, Non-Inferiority Trial
por: Poravuth, Yi, et al.
Publicado: (2011)

Ex vivo activity of the ACT new components pyronaridine and piperaquine in comparison with conventional ACT drugs against isolates of Plasmodium falciparum
por: Pascual, Aurélie, et al.
Publicado: (2012)

Pyronaridine-artesunate granules versus artemether-lumefantrine crushed tablets in children with Plasmodium falciparum malaria: a randomized controlled trial
por: Kayentao, Kassoum, et al.
Publicado: (2012)

Plasmodium-Host-Plasmodium interactions
por: Mota, Maria M
Publicado: (2010)

Species and genotype diversity of Plasmodium in malaria patients from Gabon analysed by next generation sequencing
por: Lalremruata, Albert, et al.
Publicado: (2017)

Pyronaridine–artesunate and artemether–lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a randomized controlled non-inferiority trial
por: Roth, Johanna M., et al.
Publicado: (2018)

Limitations of microscopy to differentiate Plasmodium species in a region co-endemic for Plasmodium falciparum, Plasmodium vivax and Plasmodium knowlesi
por: Barber, Bridget E, et al.
Publicado: (2013)

Efficacy, safety, and tolerability of albendazole and ivermectin based regimens for the treatment of microfilaraemic loiasis in adult patients in Gabon: A randomized controlled assessor blinded clinical trial
por: Zoleko-Manego, Rella, et al.
Publicado: (2023)

Randomized, open-label, phase 2a study to evaluate the contribution of artefenomel to the clinical and parasiticidal activity of artefenomel plus ferroquine in African patients with uncomplicated Plasmodium falciparum malaria
por: Gansane, Adama, et al.
Publicado: (2023)

Preclinical Antimalarial Combination Study of M5717, a Plasmodium falciparum Elongation Factor 2 Inhibitor, and Pyronaridine, a Hemozoin Formation Inhibitor
por: Rottmann, Matthias, et al.
Publicado: (2020)

Identification of Protein Markers in Patients Infected with Plasmodium knowlesi, Plasmodium falciparum and Plasmodium vivax
por: Mu, Alan Kang-Wai, et al.
Publicado: (2014)

Efficacy, Safety and Tolerability of Pyronaridine-artesunate in Asymptomatic Malaria-infected Individuals: a Randomized Controlled Trial
por: Dabira, Edgard D, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ida0uejnbhgac6d22vj9s3eocj